Cite
HARVARD Citation
Satlin, A. et al. (2016). Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimer's & dementia. 2 (1), pp. 1-12. [Online].